Journal articles: 'Ultrasound drug delivery'

1

Postema, Michiel, and Odd Gilja. "Ultrasound-Directed Drug Delivery." Current Pharmaceutical Biotechnology 8, no. 6 (December 1, 2007): 355–61. http://dx.doi.org/10.2174/138920107783018453.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Goertz, David, and Kullervo Hynynen. "Ultrasound-mediated drug delivery." Physics Today 69, no. 3 (March 2016): 30–36. http://dx.doi.org/10.1063/pt.3.3106.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Sonis, ST. "Ultrasound-mediated drug delivery." Oral Diseases 23, no. 2 (June 29, 2016): 135–38. http://dx.doi.org/10.1111/odi.12501.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Pua, E. C., and Pei Zhong. "Ultrasound-mediated drug delivery." IEEE Engineering in Medicine and Biology Magazine 28, no. 1 (January 2009): 64–75. http://dx.doi.org/10.1109/memb.2008.931017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Moonen, Chrit, and Ine Lentacker. "Ultrasound assisted drug delivery." Advanced Drug Delivery Reviews 72 (June 2014): 1–2. http://dx.doi.org/10.1016/j.addr.2014.04.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Zderic, Vesna. "Ultrasound enhanced ocular drug delivery." Journal of the Acoustical Society of America 153, no. 3_supplement (March 1, 2023): A67. http://dx.doi.org/10.1121/10.0018185.

Full text

Abstract:

Our objective has been to determine ultrasound parameters that can provide optimal delivery of different drugs into the eye via transcorneal and transscleral routes, study mechanisms of ultrasound action, and determine long-term safety of this approach. We showed previously that exposing cornea to therapeutic ultrasound can lead to up to 10 times more delivery of a drug-mimicking compound into the eye, with only minimal alterations in the corneal structure. Subsequently, we continued to work on drug delivery problems with clinical relevance, such as promoting delivery of antibiotics and steroids for treatment of eye inflammations. Our studies also included modeling of temperature increases in the eye during ultrasound application, effectiveness and safety of delivery of an anti-parasitic drug PHMB into the eye, and delivery of macromolecules such as Avastin via transscleral route for treatment of mascular degeneration. Our research work showed that ultrasound application can be effective and safe for delivery of drugs of different molecular sizes into the eye in vitro and in vivo. This work may eventually lead to development of an inexpensive, and non-invasive ultrasound method that can be applied in an outpatient clinic to allow targeted delivery of medications for treatment of different ocular diseases.

APA, Harvard, Vancouver, ISO, and other styles

7

Daftardar, Saloni, Rabin Neupane, Sai HS Boddu, Jwala Renukuntla, and Amit K. Tiwari. "Advances in Ultrasound Mediated Transdermal Drug Delivery." Current Pharmaceutical Design 25, no. 4 (June 3, 2019): 413–23. http://dx.doi.org/10.2174/1381612825666190211163948.

Full text

Abstract:

Low frequency ultrasound-assisted drug delivery has been widely investigated as a non-invasive method to enhance the transdermal penetration of drugs. Using this technique, a brief application of ultrasound is used to permeabilize skin for a prolonged time. In this review, an overview on ultrasound is detailed to help explain the parameters that could be modulated to obtain the desired ultrasound parameters for enhanced transdermal drug delivery. The mechanisms of enhancement and the latest developments in the area of ultrasound-assisted transdermal drug delivery are discussed. Special emphasis is placed on the effects of ultrasound when used in combination with microneedles, electroporation and iontophoresis, and penetration enhancers. Further, this review summarizes the effect of ultrasound on skin integrity and the regulatory requirements for commercialization of the ultrasound based transdermal delivery instruments.

APA, Harvard, Vancouver, ISO, and other styles

8

Tezel, Ahmet, Ashley Sens, and Samir Mitragotri. "Ultrasound mediated transdermal drug delivery." Journal of the Acoustical Society of America 112, no. 5 (November 2002): 2337. http://dx.doi.org/10.1121/1.4779436.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Zderic, Vesna, John I. Clark, Roy W. Martin, and Shahram Vaezy. "Ultrasound-Enhanced Transcorneal Drug Delivery." Cornea 23, no. 8 (November 2004): 804–11. http://dx.doi.org/10.1097/01.ico.0000134189.33549.cc.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Holland, Christy K., Jonathan A. Kopechek, Kathryn Hitchcock, Jonathan Sutton, Danielle Caudell, Gail Pyne-Geithman, Shaoling Huang, and David D. McPherson. "0277: Ultrasound Mediated Drug Delivery." Ultrasound in Medicine & Biology 35, no. 8 (August 2009): S33. http://dx.doi.org/10.1016/j.ultrasmedbio.2009.06.127.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Schoellhammer, Carl M., Avi Schroeder, Ruby Maa, Gregory Yves Lauwers, Albert Swiston, Michael Zervas, Ross Barman, et al. "Ultrasound-mediated gastrointestinal drug delivery." Science Translational Medicine 7, no. 310 (October 21, 2015): 310ra168. http://dx.doi.org/10.1126/scitranslmed.aaa5937.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Lavon, Ilana, and Joseph Kost. "Ultrasound and transdermal drug delivery." Drug Discovery Today 9, no. 15 (August 2004): 670–76. http://dx.doi.org/10.1016/s1359-6446(04)03170-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Rapoport, Natalya. "Ultrasound-mediated micellar drug delivery." International Journal of Hyperthermia 28, no. 4 (May 23, 2012): 374–85. http://dx.doi.org/10.3109/02656736.2012.665567.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Azagury, Aharon, Luai Khoury, Giora Enden, and Joseph Kost. "Ultrasound mediated transdermal drug delivery." Advanced Drug Delivery Reviews 72 (June 2014): 127–43. http://dx.doi.org/10.1016/j.addr.2014.01.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Zhou, Qiu-Lan, Zhi-Yi Chen, Yi-Xiang Wang, Feng Yang, Yan Lin, and Yang-Ying Liao. "Ultrasound-Mediated Local Drug and Gene Delivery Using Nanocarriers." BioMed Research International 2014 (2014): 1–13. http://dx.doi.org/10.1155/2014/963891.

Full text

Abstract:

With the development of nanotechnology, nanocarriers have been increasingly used for curative drug/gene delivery. Various nanocarriers are being introduced and assessed, such as polymer nanoparticles, liposomes, and micelles. As a novel theranostic system, nanocarriers hold great promise for ultrasound molecular imaging, targeted drug/gene delivery, and therapy. Nanocarriers, with the properties of smaller particle size, and long circulation time, would be advantageous in diagnostic and therapeutic applications. Nanocarriers can pass through blood capillary walls and cell membrane walls to deliver drugs. The mechanisms of interaction between ultrasound and nanocarriers are not clearly understood, which may be related to cavitation, mechanical effects, thermal effects, and so forth. These effects may induce transient membrane permeabilization (sonoporation) on a single cell level, cell death, and disruption of tissue structure, ensuring noninvasive, targeted, and efficient drug/gene delivery and therapy. The system has been used in various tissues and organs (in vitro or in vivo), including tumor tissues, kidney, cardiac, skeletal muscle, and vascular smooth muscle. In this review, we explore the research progress and application of ultrasound-mediated local drug/gene delivery with nanocarriers.

APA, Harvard, Vancouver, ISO, and other styles

16

Al Sawaftah, Nour M., and Ghaleb A. Husseini. "Ultrasound-Mediated Drug Delivery in Cancer Therapy: A Review." Journal of Nanoscience and Nanotechnology 20, no. 12 (December 1, 2020): 7211–30. http://dx.doi.org/10.1166/jnn.2020.18877.

Full text

Abstract:

The use of ultrasound as a medical diagnostic tool began in the 1940s. Ever since, the medical applications of ultrasound have included imaging, tumor ablation, and lithotripsy; however, an ever-increasing body of literature demonstrates that ultrasound has potential in other medical applications, including targeted drug delivery. Site-specific drug delivery involves delivering drugs to diseased areas with a high degree of precision, which is particularly advantageous in cancer treatment as it would minimize the adverse side effects experienced by patients. This review addresses the ability of ultrasound to induce localized and controlled drug release from nanocarriers, namely micelles and liposomes, utilizing thermal and/or mechanical effects. The interactions of ultrasound with micelles and liposomes, the effects of the lipid composition, and ultrasound parameters on the release of encapsulated drugs are discussed. In addition, a survey of the literature detailing some in vitro and in vivo ultrasound triggered drug delivery systems is presented.

APA, Harvard, Vancouver, ISO, and other styles

17

Thanou, M., and W. Gedroyc. "MRI-Guided Focused Ultrasound as a New Method of Drug Delivery." Journal of Drug Delivery 2013 (May 12, 2013): 1–12. http://dx.doi.org/10.1155/2013/616197.

Full text

Abstract:

Ultrasound-mediated drug delivery under the guidance of an imaging modality can improve drug disposition and achieve site-specific drug delivery. The term focal drug delivery has been introduced to describe the focal targeting of drugs in tissues with the help of imaging and focused ultrasound. Focal drug delivery aims to improve the therapeutic profile of drugs by improving their specificity and their permeation in defined areas. Focused-ultrasound- (FUS-) mediated drug delivery has been applied with various molecules to improve their local distribution in tissues. FUS is applied with the aid of microbubbles to enhance the permeability of bioactive molecules across BBB and improve drug distribution in the brain. Recently, FUS has been utilised in combination with MRI-labelled liposomes that respond to temperature increase. This strategy aims to “activate” nanoparticles to release their cargo locally when triggered by hyperthermia induced by FUS. MRI-guided FUS drug delivery provides the opportunity to improve drug bioavailability locally and therefore improve the therapeutic profiles of drugs. This drug delivery strategy can be directly translated to clinic as MRg FUS is a promising clinically therapeutic approach. However, more basic research is required to understand the physiological mechanism of FUS-enhanced drug delivery.

APA, Harvard, Vancouver, ISO, and other styles

18

Entzian, Kristin, and Achim Aigner. "Drug Delivery by Ultrasound-Responsive Nanocarriers for Cancer Treatment." Pharmaceutics 13, no. 8 (July 26, 2021): 1135. http://dx.doi.org/10.3390/pharmaceutics13081135.

Full text

Abstract:

Conventional cancer chemotherapies often exhibit insufficient therapeutic outcomes and dose-limiting toxicity. Therefore, there is a need for novel therapeutics and formulations with higher efficacy, improved safety, and more favorable toxicological profiles. This has promoted the development of nanomedicines, including systems for drug delivery, but also for imaging and diagnostics. Nanoparticles loaded with drugs can be designed to overcome several biological barriers to improving efficiency and reducing toxicity. In addition, stimuli-responsive nanocarriers are able to release their payload on demand at the tumor tissue site, preventing premature drug loss. This review focuses on ultrasound-triggered drug delivery by nanocarriers as a versatile, cost-efficient, non-invasive technique for improving tissue specificity and tissue penetration, and for achieving high drug concentrations at their intended site of action. It highlights aspects relevant for ultrasound-mediated drug delivery, including ultrasound parameters and resulting biological effects. Then, concepts in ultrasound-mediated drug delivery are introduced and a comprehensive overview of several types of nanoparticles used for this purpose is given. This includes an in-depth compilation of the literature on the various in vivo ultrasound-responsive drug delivery systems. Finally, toxicological and safety considerations regarding ultrasound-mediated drug delivery with nanocarriers are discussed.

APA, Harvard, Vancouver, ISO, and other styles

19

Chapla, Rachel, Katherine T. Huynh, and Carolyn E. Schutt. "Microbubble–Nanoparticle Complexes for Ultrasound-Enhanced Cargo Delivery." Pharmaceutics 14, no. 11 (November 7, 2022): 2396. http://dx.doi.org/10.3390/pharmaceutics14112396.

Full text

Abstract:

Targeted delivery of therapeutics to specific tissues is critically important for reducing systemic toxicity and optimizing therapeutic efficacy, especially in the case of cytotoxic drugs. Many strategies currently exist for targeting systemically administered drugs, and ultrasound-controlled targeting is a rapidly advancing strategy for externally-stimulated drug delivery. In this non-invasive method, ultrasound waves penetrate through tissue and stimulate gas-filled microbubbles, resulting in bubble rupture and biophysical effects that power delivery of attached cargo to surrounding cells. Drug delivery capabilities from ultrasound-sensitive microbubbles are greatly expanded when nanocarrier particles are attached to the bubble surface, and cargo loading is determined by the physicochemical properties of the nanoparticles. This review serves to highlight and discuss current microbubble–nanoparticle complex component materials and designs for ultrasound-mediated drug delivery. Nanocarriers that have been complexed with microbubbles for drug delivery include lipid-based, polymeric, lipid–polymer hybrid, protein, and inorganic nanoparticles. Several schemes exist for linking nanoparticles to microbubbles for efficient nanoparticle delivery, including biotin–avidin bridging, electrostatic bonding, and covalent linkages. When compared to unstimulated delivery, ultrasound-mediated cargo delivery enables enhanced cell uptake and accumulation of cargo in target organs and can result in improved therapeutic outcomes. These ultrasound-responsive delivery complexes can also be designed to facilitate other methods of targeting, including bioactive targeting ligands and responsivity to light or magnetic fields, and multi-level targeting can enhance therapeutic efficacy. Microbubble–nanoparticle complexes present a versatile platform for controlled drug delivery via ultrasound, allowing for enhanced tissue penetration and minimally invasive therapy. Future perspectives for application of this platform are also discussed in this review.

APA, Harvard, Vancouver, ISO, and other styles

20

Chattenton, Dani, Ian Rivens, Zheng Jiang, Diana M. Carvalho, Krit Sujarittam, Jessica K. R. Boult, Simon P. Robinson, Chris Jones, Gail ter Haar, and James Choi. "DDEL-06. Drug Delivery to the Pons Using Short-Pulse Focused Ultrasound and Microbubble Exposure for the Treatment of Diffuse Midline Glioma." Neuro-Oncology 24, Supplement_1 (June 1, 2022): i35. http://dx.doi.org/10.1093/neuonc/noac079.127.

Full text

Abstract:

Abstract Despite advances in understanding diffuse midline glioma (DMG-H3K27), including DIPG, there are still no effective treatments available, and the dismal clinical prognosis remains. This is partly because of tumour spread behind an intact blood brain barrier (BBB), preventing drug delivery and the reason for many drugs failing in the clinic. The use of focused ultrasound and intravenous microbubbles enables temporary increases in BBB permeability, allowing drugs to enter the targeted brain region. Building on recent research demonstrating that short pulses (<5 µs) of ultrasound can deliver drugs safely and uniformly to the hippocampus, we evaluated whether a similar result was achievable in the pons of mice. Mice were exposed to ultrasound (peak-negative pressure: 0.4 MPa, pulse length: 5 cycles, centre frequency 1 MHz) emitted in bursts of 38 pulses. During exposure mice received an intravenous injection of SonoVue(R) microbubbles and a fluorescently-tagged tracer (dextran, 3 kDa), acting as a drug mimic. Dextran was successfully delivered to the pons of non-tumour-bearing mice assessed by fluorescence microscopy immediately post-treatment. Dextran delivery was repeatable and confined to the targeted pons region with a homogenous distribution, typical of short pulse ultrasound, and important for treating DMG to ensure all tumour cells receive an equal drug dose. No damage to the brain was observed after H&E staining. Panobinostat has shown promise in vitro but tolerated doses have not shown therapeutic benefit in vivo as it does not cross the BBB. The in vitro toxicity of panobinostat was confirmed in a Nestin-Tv-a/p53fl/fl, RCAS-ACVR1R206H + RCAS-H3.1K27M murine cell line, with a GI50 of 15.56 nM. The ability of focused ultrasound to deliver panobinostat across the BBB to these tumours grown orthotopically will be assessed. Overall, we hope to develop a drug delivery system, that enables therapeutics to cross the BBB, expanding treatment options for DMG.

APA, Harvard, Vancouver, ISO, and other styles

21

Kim, Yoon-Seok, Min Jung Ko, Hyungwon Moon, Wonchul Sim, Ae Shin Cho, Gio Gil, and Hyun Ryoung Kim. "Ultrasound-Responsive Liposomes for Targeted Drug Delivery Combined with Focused Ultrasound." Pharmaceutics 14, no. 7 (June 21, 2022): 1314. http://dx.doi.org/10.3390/pharmaceutics14071314.

Full text

Abstract:

Chemotherapeutic drugs are traditionally used for the treatment of cancer. However, chemodrugs generally induce side effects and decrease anticancer effects due to indiscriminate diffusion and poor drug delivery. To overcome these limitations of chemotherapy, in this study, ultrasound-responsive liposomes were fabricated and used as drug carriers for delivering the anticancer drug doxorubicin, which was able to induce cancer cell death. The ultrasound-sensitive liposome demonstrated a size distribution of 81.94 nm, and the entrapment efficiency of doxorubicin was 97.1 ± 1.44%. The release of doxorubicin under the ultrasound irradiation was 60% on continuous wave and 50% by optimizing the focused ultrasound conditions. In vivo fluorescence live imaging was used to visualize the doxorubicin release in the MDA-MB-231 xenografted mouse, and it was demonstrated that liposomal drugs were released in response to ultrasound irradiation of the tissue. The combination of ultrasound and liposomes suppressed tumor growth over 56% more than liposomes without ultrasound exposure and 98% more than the control group. In conclusion, this study provides a potential alternative for overcoming the previous limitations of chemotherapeutics.

APA, Harvard, Vancouver, ISO, and other styles

22

Abadi, Danielle, and Vesna Zderic. "Ultrasound-Mediated Nail Drug Delivery System." Journal of Ultrasound in Medicine 30, no. 12 (December 2011): 1723–30. http://dx.doi.org/10.7863/jum.2011.30.12.1723.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Kost, Joseph, Drora Levy, and Robert S. Langer. "Ultrasound enhancement of transdermal drug delivery." Journal of the Acoustical Society of America 85, no. 3 (March 1989): 1399. http://dx.doi.org/10.1121/1.397338.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Hingot, Vincent, Marine Bézagu, Claudia Errico, Yann Desailly, Romain Bocheux, Mickael Tanter, and Olivier Couture. "Subwavelength far-field ultrasound drug-delivery." Applied Physics Letters 109, no. 19 (November 7, 2016): 194102. http://dx.doi.org/10.1063/1.4967009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Mullick Chowdhury, Sayan, Taehwa Lee, and Jürgen K. Willmann. "Ultrasound-guided drug delivery in cancer." Ultrasonography 36, no. 3 (July 1, 2017): 171–84. http://dx.doi.org/10.14366/usg.17021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Curra, Francesco P., and Lawrence A. Crum. "Therapeutic ultrasound: Surgery and drug delivery." Acoustical Science and Technology 24, no. 6 (2003): 343–48. http://dx.doi.org/10.1250/ast.24.343.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Shah, Robin, and Vesna Zderic. "Ultrasound‐enhanced drug delivery through sclera." Journal of the Acoustical Society of America 125, no. 4 (April 2009): 2680. http://dx.doi.org/10.1121/1.4784233.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Mo, Steven, Constantin-C. Coussios, Len Seymour, and Robert Carlisle. "Ultrasound-enhanced drug delivery for cancer." Expert Opinion on Drug Delivery 9, no. 12 (November 4, 2012): 1525–38. http://dx.doi.org/10.1517/17425247.2012.739603.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Pitt, William G., and Ghaleb A. Husseini. "Ultrasound in drug and gene delivery." Advanced Drug Delivery Reviews 60, no. 10 (June 2008): 1095–96. http://dx.doi.org/10.1016/j.addr.2008.03.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Caskey, Charles F. "Ultrasound Molecular Imaging and Drug Delivery." Molecular Imaging and Biology 19, no. 3 (March 2, 2017): 336–40. http://dx.doi.org/10.1007/s11307-017-1058-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Böhmer, Marcel R., Alexander L. Klibanov, Klaus Tiemann, Christopher S. Hall, Holger Gruell, and Oliver C. Steinbach. "Ultrasound triggered image-guided drug delivery." European Journal of Radiology 70, no. 2 (May 2009): 242–53. http://dx.doi.org/10.1016/j.ejrad.2009.01.051.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Kwan, James J., Rachel Myers, Christian M. Coviello, Susan M. Graham, Apurva R. Shah, Eleanor Stride, Robert C. Carlisle, and Constantin C. Coussios. "Ultrasound-Propelled Nanocups for Drug Delivery." Small 11, no. 39 (August 21, 2015): 5305–14. http://dx.doi.org/10.1002/smll.201501322.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Choi, Jong-ryul, and Juyoung Park. "Investigation of an Optical Imaging Platform Integrated with an Ultrasound Application System for In Vitro Verification of Ultrasound-Mediated Drug Delivery." Applied Sciences 11, no. 6 (March 22, 2021): 2846. http://dx.doi.org/10.3390/app11062846.

Full text

Abstract:

Techniques that increase the permeability of the cell membrane and transfer drugs or genes to cells have been actively developed as effective therapeutic modalities. Also, in line with the development of these drug delivery techniques, the establishment of tools to verify the techniques at the cellular level is strongly required. In this study, we demonstrated an optical imaging platform integrated with an ultrasound application system to verify the feasibility of safe and efficient drug delivery through the cell membrane using ultrasound-microbubble cavitation. To examine the potential of the platform, fluorescence images of both Fura-2 AM and propidium iodide (PI) to measure calcium flux changes and intracellular PI delivery, respectively, during and after the ultrasound-microbubble cavitation in the cervical cancer cell were acquired. Using the optical imaging platform, we determined that calcium flux increased immediately after the ultrasound-microbubble cavitation and were restored to normal levels, and fluorescence signals from intracellular PI increased gradually after the cavitation. The results acquired by the platform indicated that ultrasound-microbubble cavitation can deliver PI into the cervical cancer cell without irreversible damage of the cell membrane. The application of an additional fluorescent imaging module and high-speed imaging modalities can provide further improvement of the performance of this platform. Also, as additional studies in ultrasound instrumentations to measure real-time cavitation signals progress, we believe that the ultrasound-microbubble cavitation-based sonoporation can be employed for safe and efficient drug and gene delivery to various cancer cells.

APA, Harvard, Vancouver, ISO, and other styles

34

Kim, Kibeom, Jungmin Lee, and Myoung-Hwan Park. "Microbubble Delivery Platform for Ultrasound-Mediated Therapy in Brain Cancers." Pharmaceutics 15, no. 2 (February 19, 2023): 698. http://dx.doi.org/10.3390/pharmaceutics15020698.

Full text

Abstract:

The blood-brain barrier (BBB) is one of the most selective endothelial barriers that protect the brain and maintains homeostasis in neural microenvironments. This barrier restricts the passage of molecules into the brain, except for gaseous or extremely small hydrophobic molecules. Thus, the BBB hinders the delivery of drugs with large molecular weights for the treatment of brain cancers. Various methods have been used to deliver drugs to the brain by circumventing the BBB; however, they have limitations such as drug diversity and low delivery efficiency. To overcome this challenge, microbubbles (MBs)-based drug delivery systems have garnered a lot of interest in recent years. MBs are widely used as contrast agents and are recently being researched as a vehicle for delivering drugs, proteins, and gene complexes. The MBs are 1–10 μm in size and consist of a gas core and an organic shell, which cause physical changes, such as bubble expansion, contraction, vibration, and collapse, in response to ultrasound. The physical changes in the MBs and the resulting energy lead to biological changes in the BBB and cause the drug to penetrate it, thus enhancing the therapeutic effect. Particularly, this review describes a state-of-the-art strategy for fabricating MB-based delivery platforms and their use with ultrasound in brain cancer therapy.

APA, Harvard, Vancouver, ISO, and other styles

35

Escobar-Chavez, Jose Juan, Dalia Bonilla-Martínez, Martha Angélica Villegas-González, Isabel Marlen Rodríguez-Cruz, and Clara Luisa Domínguez-Delgado. "The Use of Sonophoresis in the Administration of Drugs Throughout the Skin." Journal of Pharmacy & Pharmaceutical Sciences 12, no. 1 (April 25, 2009): 88. http://dx.doi.org/10.18433/j3c30d.

Full text

Abstract:

Abstract Transdermal drug delivery offers an attractive alternative to the conventional drug delivery methods of oral administration and injection. However, the stratum corneum acts as a barrier that limits the penetration of substances through the skin. Application of ultrasound to the skin increases its permeability (sonophoresis) and enables the delivery of various substances into and through the skin. Ultrasound has been used extensively for medical diagnostics and to a certain extent in medical therapy (physiotherapy, ultrasonic surgery, hyperthermia). Nevertheless, it has only recently become popular as a technique to enhance drug release from drug delivery systems. A number of studies suggest the use of ultrasound as an external mean of delivering drugs at increased rates and at desired times. This review presents the main findings in the field of sonophoresis, namely transdermal drug delivery and transdermal monitoring. Particular attention is paid to proposed enhancement mechanisms and trends in the field of topical and transdermal delivery.

APA, Harvard, Vancouver, ISO, and other styles

36

Chen, Hong, Cherry C. Chen, Camilo Acosta, Shih-Ying Wu, Tao Sun, and Elisa E. Konofagou. "A New Brain Drug Delivery Strategy: Focused Ultrasound-Enhanced Intranasal Drug Delivery." PLoS ONE 9, no. 10 (October 3, 2014): e108880. http://dx.doi.org/10.1371/journal.pone.0108880.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Ferrara, Katherine W., Mark A. Borden, Paul A. Dayton, Azi Kheirolomoom, Dustin E. Kruse, Michaelann Tartis, and Aaron F. Lum. "Enhanced drug delivery with ultrasound and engineered delivery vehicles." Journal of the Acoustical Society of America 119, no. 5 (May 2006): 3255–56. http://dx.doi.org/10.1121/1.4786080.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Allison, Claire M., Annette Jimenez-Benoit, Krishna Ramajayam, Dieter Haemmerich, and Vesna Zderic. "Therapeutic ultrasound for enhanced transcorneal macromolecule delivery." Journal of the Acoustical Society of America 153, no. 3_supplement (March 1, 2023): A67. http://dx.doi.org/10.1121/10.0018186.

Full text

Abstract:

Previous experiments demonstrated that ultrasound exposure at 400-600 kHz can increase transcorneal drug delivery of sodium-fluorescein. Our study aims to determine if these same methods can enhance the delivery of fluorescently labeled FITC-dextran macromolecules of similar molecular weights to clinically relevant drugs. Dissected corneas of adult rabbits were placed in a diffusion cell between a donor compartment filled with a solution of FITC-dextran macromolecules diluted with phosphate-buffered saline (PBS) to 1 mg/ml and a receiver compartment filled with PBS. Each cornea was exposed to the drug solution for 60 minutes, with the experimental group receiving 5 min of continuous ultrasound or 10 min of pulsed ultrasound at 50% duty cycle at the beginning of treatment. Unfocused circular ultrasound transducers were operated at 0.5 –1 W/cm2 intensity and at 600 kHz frequency. Macromolecule delivery was quantified by the fluorescence intensity detected in the receiver compartment. The greatest increase in transcorneal drug delivery seen was 1.2 times (p < 0.05) with the application of pulsed ultrasound at 0.5 W/cm2 and 600 kHz for 10 min with 40 kDa macromolecules. Gross observation of corneas after experiments demonstrated no significant damage. Ongoing microscopy and thermal-modeling studies aim to characterize any ultrasound-induced damage.

APA, Harvard, Vancouver, ISO, and other styles

39

Barzegar-Fallah, Anita, Kushan Gandhi, Shakila B. Rizwan, Tania L. Slatter, and John N. J. Reynolds. "Harnessing Ultrasound for Targeting Drug Delivery to the Brain and Breaching the Blood–Brain Tumour Barrier." Pharmaceutics 14, no. 10 (October 19, 2022): 2231. http://dx.doi.org/10.3390/pharmaceutics14102231.

Full text

Abstract:

Despite significant advances in developing drugs to treat brain tumours, achieving therapeutic concentrations of the drug at the tumour site remains a major challenge due to the presence of the blood–brain barrier (BBB). Several strategies have evolved to enhance brain delivery of chemotherapeutic agents to treat tumours; however, most approaches have several limitations which hinder their clinical utility. Promising studies indicate that ultrasound can penetrate the skull to target specific brain regions and transiently open the BBB, safely and reversibly, with a high degree of spatial and temporal specificity. In this review, we initially describe the basics of therapeutic ultrasound, then detail ultrasound-based drug delivery strategies to the brain and the mechanisms by which ultrasound can improve brain tumour therapy. We review pre-clinical and clinical findings from ultrasound-mediated BBB opening and drug delivery studies and outline current therapeutic ultrasound devices and technologies designed for this purpose.

APA, Harvard, Vancouver, ISO, and other styles

40

Duncan, Blair, Raida Al-Kassas, Guangming Zhang, Dave Hughes, and Yongqiang Qiu. "Ultrasound-Mediated Ocular Drug Delivery: From Physics and Instrumentation to Future Directions." Micromachines 14, no. 8 (August 9, 2023): 1575. http://dx.doi.org/10.3390/mi14081575.

Full text

Abstract:

Drug delivery to the anterior and posterior segments of the eye is impeded by anatomical and physiological barriers. Increasingly, the bioeffects produced by ultrasound are being proven effective for mitigating the impact of these barriers on ocular drug delivery, though there does not appear to be a consensus on the most appropriate system configuration and operating parameters for this application. In this review, the fundamental aspects of ultrasound physics most pertinent to drug delivery are presented; the primary phenomena responsible for increased drug delivery efficacy under ultrasound sonication are discussed; an overview of common ocular drug administration routes and the associated ocular barriers is also given before reviewing the current state of the art of ultrasound-mediated ocular drug delivery and its potential future directions.

APA, Harvard, Vancouver, ISO, and other styles

41

Ingram, Nicola, Laura E. McVeigh, Radwa H. Abou-Saleh, Damien V. B. Batchelor, Paul M. Loadman, James R. McLaughlan, Alexander F. Markham, Stephen D. Evans, and P. Louise Coletta. "A Single Short ‘Tone Burst’ Results in Optimal Drug Delivery to Tumours Using Ultrasound-Triggered Therapeutic Microbubbles." Pharmaceutics 14, no. 3 (March 11, 2022): 622. http://dx.doi.org/10.3390/pharmaceutics14030622.

Full text

Abstract:

Advanced drug delivery systems, such as ultrasound-mediated drug delivery, show great promise for increasing the therapeutic index. Improvements in delivery by altering the ultrasound parameters have been studied heavily in vitro but relatively little in vivo. Here, the same therapeutic microbubble and tumour type are used to determine whether altering ultrasound parameters can improve drug delivery. Liposomes were loaded with SN38 and attached via avidin: biotin linkages to microbubbles. The whole structure was targeted to the tumour vasculature by the addition of anti-vascular endothelial growth factor receptor 2 antibodies. Tumour drug delivery and metabolism were quantified in SW480 xenografts after application of an ultrasound trigger to the tumour region. Increasing the trigger duration from 5 s to 2 min or increasing the number of 5 s triggers did not improve drug delivery, nor did changing to a chirp trigger designed to stimulate a greater proportion of the microbubble population, although this did show that the short tone trigger resulted in greater release of free SN38. Examination of ultrasound triggers in vivo to improve drug delivery is justified as there are multiple mechanisms at play that may not allow direct translation from in vitro findings. In this setting, a short tone burst gives the best ultrasound parameters for tumoural drug delivery.

APA, Harvard, Vancouver, ISO, and other styles

42

Lamsam, Layton, Eli Johnson, Ian D. Connolly, Max Wintermark, and Melanie Hayden Gephart. "A review of potential applications of MR-guided focused ultrasound for targeting brain tumor therapy." Neurosurgical Focus 44, no. 2 (February 2018): E10. http://dx.doi.org/10.3171/2017.11.focus17620.

Full text

Abstract:

Magnetic resonance–guided focused ultrasound (MRgFUS) has been used extensively to ablate brain tissue in movement disorders, such as essential tremor. At a lower energy, MRgFUS can disrupt the blood-brain barrier (BBB) to allow passage of drugs. This focal disruption of the BBB can target systemic medications to specific portions of the brain, such as for brain tumors. Current methods to bypass the BBB are invasive, as the BBB is relatively impermeable to systemically delivered antineoplastic agents. Multiple healthy and brain tumor animal models have suggested that MRgFUS disrupts the BBB and focally increases the concentration of systemically delivered antitumor chemotherapy, immunotherapy, and gene therapy. In animal tumor models, combining MRgFUS with systemic drug delivery increases median survival times and delays tumor progression. Liposomes, modified microbubbles, and magnetic nanoparticles, combined with MRgFUS, more effectively deliver chemotherapy to brain tumors. MRgFUS has great potential to enhance brain tumor drug delivery, while limiting treatment toxicity to the healthy brain.

APA, Harvard, Vancouver, ISO, and other styles

43

Endo-Takahashi, Yoko, Kazuo Maruyama, and Yoichi Negishi. "Nucleic Acid Delivery System by the Combination of Lipid bubbles and Ultrasound." Current Pharmaceutical Design 24, no. 23 (October 24, 2018): 2673–77. http://dx.doi.org/10.2174/1381612824666180807122759.

Full text

Abstract:

Background: RNA interference (RNAi)-based therapy has gained attention because of its potent genesilencing effect and high specificity. However, the efficient delivery of nucleic acids to the target site is a major challenge to the clinical implementation. Recently, ultrasound-mediated gene delivery systems have been developed and attracted interest due to its safety and site-specificity. By the combination with contrast agents, called microbubbles, not only the delivery effects but also the imaging effects are significantly enhanced. We developed lipid bubbles (LBs) entrapping an ultrasound contrast gas to enhance the efficacy of ultrasound-mediated delivery and imaging. In this review, we summarize ultrasound-mediated nucleic acid delivery systems and discuss the possibility of combining LBs and ultrasound for RNAi-based therapies. Methods: We prepared polyethylene glycol-modified liposomes and entrapped an echo-contrast gas within the liposomes. Small interfering RNA (siRNA) were transfected into cells and muscles using LBs and ultrasound. Moreover, we also developed nucleic acid-loaded LBs using cholesterol-conjugated siRNA or positively-charged lipid for an efficient systemic delivery of siRNA and microRNA. The usability of LBs for RNA delivery system was evaluated by the silencing effects of target genes and the therapeutic effects on ischemia hind limb. Results: A combination of LBs and therapeutic ultrasound was able to enhance the gene silencing effects by siRNA. Nucleic acid-loaded LBs were able to efficiently deliver siRNA or microRNA by systemic administration. A combination of LBs and diagnostic ultrasound also enhanced the imaging efficiency. Using a hindlimb ischemia mouse model, microRNA-loaded LBs could lead to increased angiogenic factors and improved blood flow. Conclusion: Ultrasound technology is widely used in clinical settings not only for diagnosis but also for therapy. Ultrasonic devices are being actively developed. Computer-controlled ultrasound systems can provide precise exposure to the target site. The combination of precise ultrasound exposure and LBs might be useful for target site-specific nucleic acids delivery, and holds potential to be developed into a beneficial therapeutic and diagnostic system for various diseases.

APA, Harvard, Vancouver, ISO, and other styles

44

Osei, Ernest, and Aladdin Al-Asady. "A review of ultrasound-mediated microbubbles technology for cancer therapy: a vehicle for chemotherapeutic drug delivery." Journal of Radiotherapy in Practice 19, no. 3 (August 22, 2019): 291–98. http://dx.doi.org/10.1017/s1460396919000633.

Full text

Abstract:

AbstractBackground:The unique behaviour of microbubbles under ultrasound acoustic pressure makes them useful agents for drug and gene delivery. Several studies have demonstrated the potential application of microbubbles as a non-invasive, safe and effective technique for targeted delivery of drugs and genes. The drugs can be incorporated into the microbubbles in several different approaches and then carried to the site of interest where it can be released by destruction of the microbubbles using ultrasound to achieve the required therapeutic effect.Methods:The objective of this article is to report on a review of the recent advances of ultrasound-mediated microbubbles as a vehicle for delivering drugs and genes and its potential application for the treatment of cancer.Conclusion:Ultrasound-mediated microbubble technology has the potential to significantly improve chemotherapy drug delivery to treatment sites with minimal side effects. Moreover, the technology can induce temporary and reversible changes in the permeability of cells and vessels, thereby allowing for drug delivery in a spatially localised region which can improve the efficiency of drugs with poor bioavailability due to their poor absorption, rapid metabolism and rapid systemic elimination.

APA, Harvard, Vancouver, ISO, and other styles

45

Khan, Aaqib H., Sapna Bisht, Nishita Mistry, Karla Patricia Mercado-Shekhar, and Sameer V. Dalvi. "Ultrasound responsive multi-layered emulsions for drug delivery." Journal of the Acoustical Society of America 155, no. 3_Supplement (March 1, 2024): A286. http://dx.doi.org/10.1121/10.0027523.

Full text

Abstract:

Vaporizable double emulsions, characterized by a central aqueous core, have demonstrated effectiveness in encapsulating hydrophilic drugs. This study aims to investigate the potential of incorporating an additional oil- layer in the double emulsions to encapsulate hydrophobic drugs. Vaporizable multi-layered emulsions were produced in three steps using perfluoropentane (PFP), phosphate-buffered saline (PBS), and sunflower oil. Curcumin, a natural anti-inflammatory drug, was dispersed in the oil phase. Krytox, polyglycerol polyricinoleate, and bovine serum albumin (BSA) were used as surfactants. PFP was sonicated in PBS (1:6) for 1 minute to create emulsion-1. Subsequently, emulsion-1 (1:4) was homogenized in oil to make emulsion-2. Emulsion-2 was homogenized in BSA (1:4) to yield emulsion-3 at 8000 rpm for 30 seconds. The vaporization pressure threshold was determined using 2 MHz focused ultrasound with a single-element transducer (f/# of 1.27, 0.5% duty cycle). B-mode imaging was conducted using a Verasonics Vantage 128 system with an L11-5v array to determine the droplet vaporization threshold, which was found to be 6.7 MPa. Curcumin-loading (0.87 ± 0.1 mg) was significantly higher in the multi-layered emulsions than in single-layered BSA-shelled microbubbles (0.019 ± 0.004 mg) (p < 0.00001), indicating that multi-layered emulsions exhibit higher drug loading capacity.

APA, Harvard, Vancouver, ISO, and other styles

46

Tachibana, Katsuro, and Shunro Tachibana. "Application of ultrasound energy as a new drug delivery system." Folia Pharmacologica Japonica 114, supplement (1999): 138–41. http://dx.doi.org/10.1254/fpj.114.supplement_138.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Honari, Arvin, and Shashank R. Sirsi. "The Evolution and Recent Trends in Acoustic Targeting of Encapsulated Drugs to Solid Tumors: Strategies beyond Sonoporation." Pharmaceutics 15, no. 6 (June 10, 2023): 1705. http://dx.doi.org/10.3390/pharmaceutics15061705.

Full text

Abstract:

Despite recent advancements in ultrasound-mediated drug delivery and the remarkable success observed in pre-clinical studies, no delivery platform utilizing ultrasound contrast agents has yet received FDA approval. The sonoporation effect was a game-changing discovery with a promising future in clinical settings. Various clinical trials are underway to assess sonoporation’s efficacy in treating solid tumors; however, there are disagreements on its applicability to the broader population due to long-term safety issues. In this review, we first discuss how acoustic targeting of drugs gained importance in cancer pharmaceutics. Then, we discuss ultrasound-targeting strategies that have been less explored yet hold a promising future. We aim to shed light on recent innovations in ultrasound-based drug delivery including newer designs of ultrasound-sensitive particles specifically tailored for pharmaceutical usage.

APA, Harvard, Vancouver, ISO, and other styles

48

Husseini, Ghaleb A., and William G. Pitt. "The Use of Ultrasound and Micelles in Cancer Treatment." Journal of Nanoscience and Nanotechnology 8, no. 5 (May 1, 2008): 2205–15. http://dx.doi.org/10.1166/jnn.2008.225.

Full text

Abstract:

The high toxicity of potent chemotherapeutic drugs like Doxorubicin (Dox) limits the therapeutic window in which they can be applied. This window can be expanded by controlling the drug delivery in both space and time such that non-targeted tissues are not adversely affected. Recent research has shown that ultrasound (US) can be used to control the release of Dox and other hydrophobic drugs from polymeric micelles in both time and space. It has also been shown using an in vivo rat tumor model that Dox activity can be enhanced by ultrasound in one region, while in an adjacent region there is little or no effect of the drug. In this article, we review the in vivo and in vitro research being conducted in the area of using ultrasound to enhance and target micellar drug delivery to cancerous tissues. Additionally, we summarize our previously published mathematical models that attempt to represent the release and re-encapsulation phenomena of Dox from Pluronic® P105 micelles upon the application of ultrasound. The potential benefits of such controlled chemotherapy compels a thorough investigation of the role of ultrasound (US) and the mechanisms by which US accomplishes drug release and/or enhances drug potency. Therefore we will summarize our findings related to the mechanism involved in acoustically activated micellar drug delivery to tumors.

APA, Harvard, Vancouver, ISO, and other styles

49

Wei, Ping, Erik Jan Cornel, and Jianzhong Du. "Ultrasound-responsive polymer-based drug delivery systems." Drug Delivery and Translational Research 11, no. 4 (March 24, 2021): 1323–39. http://dx.doi.org/10.1007/s13346-021-00963-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Tachibana, Katsuro, and Shunro Tachibana. "The Use of Ultrasound for Drug Delivery." Echocardiography 18, no. 4 (May 2001): 323–28. http://dx.doi.org/10.1046/j.1540-8175.2001.00323.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Ultrasound drug delivery'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles